tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Venus Medtech Schedules Board Meeting to Review Interim Results

Story Highlights
Venus Medtech Schedules Board Meeting to Review Interim Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) just unveiled an announcement.

Venus Medtech (Hangzhou) Inc. has announced a board meeting scheduled for August 28, 2025, to review and approve the interim results for the first half of 2025. The meeting will also consider the recommendation of an interim dividend and address other business matters, potentially impacting the company’s financial strategy and stakeholder interests.

More about Venus Medtech (Hangzhou), Inc. Class H

Venus Medtech (Hangzhou) Inc. is a company incorporated in the People’s Republic of China, operating in the medical technology industry. It focuses on developing and providing innovative medical devices, particularly in the cardiovascular field.

Average Trading Volume: 4,686,120

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.98B

For an in-depth examination of 2500 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1